AI Analysis | Feedback

Here are 1-2 brief analogies to describe Revelation Biosciences (REVB):

• Essentially the clinical-stage drug development arm of a major pharmaceutical company like Pfizer or Merck, but operating as an independent, much smaller public company.
• A clinical-stage version of an early Regeneron Pharmaceuticals, focused on developing novel therapies for inflammatory and immunological diseases.

AI Analysis | Feedback

REV-STAT (bomaclor)

REV-BLOC (bomaclor)

REV-IR (bomaclor)

AI Analysis | Feedback

Revelation Biosciences (REVB) is a **clinical-stage biopharmaceutical company**. This means the company is primarily focused on the research, development, and clinical trials of drug candidates for the prevention and treatment of infectious diseases and inflammatory conditions.

As a company currently in the clinical development phase, Revelation Biosciences **does not have approved products on the market that it sells to traditional customers.** Therefore, it does not have "major customers" in the conventional sense of entities purchasing its products or services.

Its operations are typically funded through sources such as:

• Investments (e.g., equity financing, private placements from institutional or individual investors)
• Grants from governmental or non-profit organizations
• Potential future partnerships or collaborations with larger pharmaceutical companies, which would be strategic alliances for co-development or licensing rather than customer relationships for product sales.

The company's objective is to advance its drug candidates through clinical trials and regulatory approval. If successful, it would then aim to commercialize products, either independently or through partnerships, to reach patients via healthcare providers, pharmacies, or distributors.

AI Analysis | Feedback

AI Analysis | Feedback

James Rolke, Chairman and Chief Executive Officer

Mr. Rolke cofounded Revelation Biosciences in May 2020 and has served as CEO since its inception. He has over 30 years of experience in the biotechnology industry, covering all aspects of drug development. Prior to Revelation, Mr. Rolke was at La Jolla Pharmaceutical Company from 2012 to 2020, where he held various leadership roles, including Chief Scientific Officer from 2017 to 2020. During his time at La Jolla, he oversaw the development of multiple technologies, including six INDs and two marketing approvals for Giapreza and artesunate. Before La Jolla, from 2009 to 2012, Mr. Rolke was Chief Technology Officer at Pluromed, Inc., which was acquired by Sanofi, and played a key role in the approval of two medical devices. He also held significant positions at other biotechnology companies such as Director of Operations at Prospect Therapeutics, Inc., Associate Director of Pharmaceutical Development at Mersana Therapeutics, Inc., Manager of Process Development at GlycoGenesys, Inc., Principal Scientist at Surgical Sealants, Inc., Scientist at GelTex, Inc., and Associate Scientist at Alpha-Beta Technology, Inc.

Chester Zygmont, III, Chief Financial Officer

Mr. Zygmont has served as Revelation Biosciences' Chief Financial Officer since the company's inception. He brings over 20 years of experience in finance with a wide range of industry applications.

Robin Marsden, Senior Vice President, Biology

Ms. Marsden has over 25 years of experience in biotechnology. Her experience includes successfully executing the bioanalytical and immunogenicity strategy for three FDA-approved products: Symlin and Byetta (both from Astra-Zeneca, formerly Amylin) and Giapreza (La Jolla Pharmaceutical). Most recently, she was Senior Director at La Jolla Pharmaceutical, where she oversaw a team of research associates and scientists responsible for preclinical, bioanalytical, and biologics disciplines. At Revelation Biosciences, Ms. Marsden supports R&D activities, including providing scientific rationale for corporate strategy, writing patents and regulatory submissions, and overseeing outsourced activities.

Carol Odle, Vice President, Clinical Operations

AI Analysis | Feedback

The key risks for Revelation Biosciences (REVB) are:

1. Limited Operating History and No Approved Products: Revelation Biosciences is a clinical-stage life sciences company with a limited operating history and no products approved for commercial sale. It has incurred net losses since its inception and anticipates continuing to incur significant losses for the foreseeable future, potentially never achieving or maintaining profitability. As a pre-revenue company, its outlook is highly dependent on clinical progress and future regulatory milestones.
2. Clinical Development and Regulatory Approval Risks: The company's business is heavily dependent on the successful development and regulatory approval of its product candidates, primarily from its Gemini platform. There are inherent risks in clinical trials, including the ability to successfully complete planned studies, potential delays in enrollment, and the occurrence of adverse safety events or unexpected concerns arising from clinical data. For example, three severe adverse events were reported at the highest dose of Gemini in an early-stage trial, though they were transient. Furthermore, significant reductions in FDA staffing and changes in federal regulatory policy may delay or adversely affect the approval and commercialization of its product candidates.
3. Financial Instability and Dilution Risk: Revelation Biosciences sustains its activities through external financing, leading to ongoing net losses. While the company has reported some cash runway, its financial health and ability to continue operations rely on its capacity to secure additional funding, which can lead to dilution for existing shareholders through new share offerings or warrant exercises. The company has also received non-compliance letters from Nasdaq regarding its minimum bid price, indicating a potential risk to its listing status and reflecting significant declines in its stock price.

AI Analysis | Feedback

The rapid advancement and application of messenger RNA (mRNA) vaccine technology by well-capitalized pharmaceutical companies represents a clear emerging threat. Companies like Moderna, Pfizer, and BioNTech are actively utilizing their mRNA platforms to develop vaccines for influenza (including universal flu vaccine candidates), RSV, and other respiratory viral infections. This directly overlaps with Revelation Biosciences' pipeline, particularly REV-VAC (universal flu vaccine) and potentially REV-ARIA. The demonstrated speed of development, high efficacy, and the potential for broad-spectrum protection and combination vaccines (e.g., flu, RSV, COVID in a single shot) inherent in mRNA technology poses a significant competitive challenge to Revelation Biosciences' more traditional or peptide-based immunomodulatory approaches.

AI Analysis | Feedback

AI Analysis | Feedback

Expected Drivers of Future Revenue Growth for Revelation Biosciences (REVB)

Revelation Biosciences (REVB) is a clinical-stage biopharmaceutical company primarily focused on developing immune system therapeutics. Over the next 2-3 years, its future revenue growth is expected to be driven by advancements in its proprietary drug candidate, Gemini, across multiple therapeutic indications, coupled with potential strategic partnerships.

1. Advancement and Commercialization of Gemini in Key Indications

   The primary driver of future revenue growth for Revelation Biosciences is the successful clinical development and eventual commercialization of its lead asset, Gemini, a proprietary intravenous therapy designed to modulate inflammation. The company is actively progressing several programs:

   • GEM-PBI (Post-Burn Infection): Revelation Biosciences anticipates interim data from trials for GEM-PBI in the third quarter of 2025. Positive results could advance this program towards later-stage clinical development and potential market entry.
   • GEM-AKI (Acute Kidney Injury): The company projects a potential Phase 2 start for GEM-AKI in early 2026. Successful progression in this indication, which has shown protective effects in preclinical studies, represents a significant growth opportunity.
   • GEM-CKD (Chronic Kidney Disease): Revelation Biosciences has reported positive Phase 1b clinical study results for GEM-CKD, demonstrating a significant and durable reduction of inflammation in chronic kidney disease patients. Continued positive outcomes and progression in trials would be crucial for future revenue.
   • GEM-PSI (Post-Surgical Infection): This program is being developed through a licensing agreement, indicating a potential pathway to address healthcare-associated bacterial infections.

2. Strategic Partnerships and Funding Opportunities

   As a clinical-stage company, securing strategic partnerships will be a significant driver for Revelation Biosciences. Successful achievement of clinical milestones, particularly positive Phase 2 readouts for its Gemini programs, could attract collaborators and unlock further funding opportunities essential for late-stage development and commercialization efforts.

3. Expansion of the Product Pipeline beyond Gemini

   While Gemini is the flagship candidate, the broader pipeline includes other potential therapeutics. The advancement of candidates such as REVTx-99b for nasal congestion and allergic rhinitis, and REVTx-300 for chronic organ diseases, represents additional avenues for future revenue generation. Although these may be in earlier stages, their progression through clinical development could diversify Revelation Biosciences' revenue streams in the longer term.

AI Analysis | Feedback

Share Issuance

• In September 2025, Revelation Biosciences received approximately $9.6 million in gross proceeds from the immediate exercise of 4,355,000 outstanding Class H warrants. As part of this transaction, new Class I warrants to purchase up to 13,065,000 shares of common stock were issued in a private placement, exercisable at $2.20 per share.
• In May 2025, the company closed a public offering, generating approximately $4 million in gross proceeds from the sale of 3,640,000 shares of common stock (or equivalents) and warrants to purchase up to 14,560,000 shares.
• In December 2024, Revelation Biosciences received $3.7 million in net proceeds from the exercise of warrants.

Inbound Investments

• Revelation Biosciences received $9.1 million in a "Post IPO" funding round in January 2021, with the Global Health Investment Fund participating as an institutional investor.

Outbound Investments

• Revelation Biosciences has not made any investments or acquisitions during the last 3-5 years.

Capital Expenditures

• Capital expenditures for Revelation Biosciences were reported as $17,689 in the last 12 months.
• Historical data indicates capital expenditures of $49K, likely for a recent annual or trailing twelve-month period.